Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

SKIN CANCER

The new era of adjuvant therapies for melanoma

Nature Reviews Clinical Oncology volume 15, pages 535–536 (2018)Cite this article

Subjects

New treatment options for patients with resected stage III melanoma have been established with the publication of the results of four pivotal randomized clinical trials, resulting in three drug approvals, with a forth expected, all within only 4 years. Herein, we put these advances into context.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Kaplan–Meier curves of estimated RFS in key trials of adjuvant therapies for melanoma2,3,4,5.

References

  1. Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur. J. Cancer 83, 247–257 (2017).

    Article  PubMed  Google Scholar 

  2. Eggermont, A. M. Prolonged survival with Ipilimumab as adjuvant in stage III melanoma. N. Engl. J. Med. 375, 1845–1855 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).

    Article  PubMed  CAS  Google Scholar 

  4. Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).

    Article  PubMed  CAS  Google Scholar 

  5. Eggermont, A. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789–1801 (2018).

    Article  PubMed  CAS  Google Scholar 

  6. Ives, N. J. et al. Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur. J. Cancer 82, 171–183 (2017).

    Article  PubMed  CAS  Google Scholar 

  7. Leiter, U. et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 17, 757–767 (2016).

    Article  PubMed  Google Scholar 

  8. Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Verver, D. et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur. J. Cancer. 96, 25–33 (2018).

    Article  PubMed  Google Scholar 

  10. Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181–193 (2018).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gustave Roussy Comprehensive Cancer Centre, Villejuif, France

    Alexander M. M. Eggermont & Caroline Robert

  2. Université Paris-Saclay, Villejuif, France

    Alexander M. M. Eggermont & Caroline Robert

  3. Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA

    Antoni Ribas

Authors
  1. Alexander M. M. Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antoni Ribas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander M. M. Eggermont.

Ethics declarations

Competing interests

A.M.M.E. has received consulting and/or advisory board fees from Actelion, Agenus, Bayer, Bristol-Myers Squibb (BMS), Ellipses, GlaxoSmithKline (GSK), HalioDX, Incyte, MedImmune, Merck, Sharp & Dohme (MSD), Merck-Serono, Nektar, Novartis, Pfizer, and Sanofi. C.R. has received consulting and/or advisory board fees from Amgen, BMS, GSK, Merck, Novartis, and Roche. A.R. has received consulting and/or advisory board fees from Amgen, BMS, Chugai, Genentech, Merck, Novartis, and Roche and is on the scientific advisory board of Arcus, BioncoTech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Lutris, Programme of Action for Cancer Therapy (PACT), Rgenix, and Tango.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eggermont, A.M.M., Robert, C. & Ribas, A. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol 15, 535–536 (2018). https://doi.org/10.1038/s41571-018-0048-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-018-0048-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing